- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Intercept Pharmaceuticals Inc
+ Add to WatchlistICPT:US
32.9000 USD 1.5700 4.55%As of 20:10:00 ET on 05/22/2013.
Snapshot for Intercept Pharmaceuticals Inc (ICPT)
| Open: | 34.4300 | Day's Range: | 32.6700 - 34.5100 | Volume: | 27,107 |
|---|---|---|---|---|---|
| Previous Close: | 32.9000 | 52wk Range: | 15.0000 - 42.6700 | 1-Yr Rtn: | - |
Key Statistics for ICPT
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -1.9120 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 552.89 |
| Shares Outstanding (M) | 16.81 |
| 30 Day Average Volume | 41,117 |
| Price/Book (mrq) | 9.0009 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/15/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ICPT
Company Profile & Key Executives for ICPT
Intercept Pharmaceuticals Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept Pharmaceuticals serves customers throughout the United States.
| Mark PruzanskiPresident/CEO/Co-Founder | Barbara DuncanCFO/Treasurer/Secretary |
| Luciano AdoriniChief Scientific Officer | Daniel P ReganChief Commercial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ICPT News
-
Industry News
No stories found
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page